Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.59 |
| ▸ | CTSS | P25774 | 5/20 | 0.56 |
| ▸ | PPARG | P37231 | 2/20 | 0.54 |
| ▸ | KLK7 | P49862 | 3/20 | 0.52 |
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.52 |
| ▸ | SYK | P43405 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 5/20 | 0.47 |
| ▸ | CTSL | P07711 | 2/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8697793 | 0.91 | PPARA (0.65) | PPARACTSSPPARGKLK7KLK5 | |
| SCHEMBL7518373 | 0.88 | PPARA (0.74) | PPARACTSSPPARGKLK7KLK5 | |
| SCHEMBL19853661 | 0.88 | PPARA (0.74) | PPARACTSSPPARGKLK7KLK5 | |
| SCHEMBL697557 | 0.87 | L3MBTL1 (0.52) | PPARACTSSPPARGKLK7KLK5 | |
| SCHEMBL20905753 | 0.86 | CTSS (0.50) | PPARACTSSPPARGKLK7KLK5 | |
| SCHEMBL18526468 | 0.86 | PPARA (0.55) | PPARACTSSPPARGKLK7KLK5 | |
| SCHEMBL29828584 | 0.86 | KLK7 (0.55) | PPARACTSSPPARGKLK7KLK5 | |
| SCHEMBL8195832 | 0.84 | KYNU (0.55) | CTSSCTSKCTSLCTSB | |
| SCHEMBL8138595 | 0.83 | PPARA (0.60) | PPARACTSSPPARGKLK7KLK5 | |
| SCHEMBL31372427 | 0.83 | PPARA (0.60) | PPARACTSSPPARGKLK7KLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357319-A1 | PROTEASOME INHIBITORS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2023-11-09 | — | — | US | disclosed |
| US-20230357319-A1 | PROTEASOME INHIBITORS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2023-11-09 | — | — | US | disclosed |
| US-11578101-B2 | Proteasome inhibitors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2023-02-14 | — | — | US | disclosed |
| US-20210309695-A1 | PROTEASOME INHIBITORS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2021-10-07 | — | — | US | disclosed |
| WO-2020033437-A1 | PROTEASOME INHIBITORS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2020-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11578101-B2 | Proteasome inhibitors | PSMG3, PSME1, PSMB1 | PPARA 4012/4885CTSS 1342/4885PPARG 4153/4885 |
| US-20210309695-A1 | PROTEASOME INHIBITORS | PSMG3, PSME1, PSMB1 | PPARA 4012/4885CTSS 1342/4885PPARG 4153/4885 |
| US-20230357319-A1 | PROTEASOME INHIBITORS | PSMG3, PSME1, PSMB1 | PPARA 4012/4885CTSS 1342/4885PPARG 4153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.